NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021

by Ed Johnson
September 11, 2021
A A

–Final results from PROviDE, a long-term, real-world study, evaluating the effectiveness of DUODOPA® (levodopa-carbidopa intestinal gel) in patients with advanced Parkinson’s disease
–Additional poster presentations planned on the real-world efficacy and safety of BOTOX® (onabotulinumtoxinA) for the treatment of spasticity and cervical dystonia
–Research highlights AbbVie’s continued focus on advancing the management of movement disorders

NORTH CHICAGO, Ill., Sept. 10, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22. More than 20 abstracts across disease states, including Parkinson’s disease, spasticity and cervical dystonia, will be presented.

“At AbbVie, we are committed to addressing the unmet needs of people living with a wide range of movement disorders,” said Sebastian Sorsaburu, MD, vice president, global specialty care medical affairs, AbbVie. “Our research presented at MDS 2021 builds upon our expertise in neuroscience and reinforces our mission to advance the standards of care for people living with these debilitating diseases.”

Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.

Key AbbVie abstracts for the MDS Virtual Congress 2021, which will all be available as virtual e-posters beginning at 8:00 a.m. CDT on September 10, are outlined below.

Key AbbVie Abstracts at MDS 2021
Abstract Title
DUODOPA® Abstracts
Dyskinesia, Pain, and Quality of Life in Parkinson’s Disease: Post Hoc Analysis from the DYSCOVER Study
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients with Motor Fluctuations and Dyskinesia Managed with Oral Dopaminergic Therapies Versus Device-Aided Therapies
Impact on Dyskinesia in Advanced Parkinson’s Disease Patients Treated with LCIG: Analysis from the COSMOS Study
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Patients with Advanced Parkinson’s Disease
Long-Term Real-World Effectiveness of Carbidopa/Levodopa Enteral Suspension After 36 Months of Treatment Initiation: Final Results from PROviDE Study
Levodopa/Carbidopa Intestinal Gel (LCIG) Reduces Fluctuations and Shortens Time to On Without Troublesome Dyskinesia in Advanced Parkinson’s Disease: Post-Hoc Analyses of 54-week LCIG-Monotherapy Trial
Real-World Characteristics of Advanced Parkinson’s Disease Patients Initiating Carbidopa/Levodopa Enteral Suspension
Impact of Device-Aided Therapies on QoL and Off-Time Improvement in Advanced Parkinson’s Disease Patients: Comparative Effectiveness Results from a Bayesian Network Meta-Analysis
Overview of the Population of Patients with Advanced Parkinson’s Disease (aPD) Initiating Therapy with Levodopa-Carbidopa Intestinal Gel (LCIG): POMPE-PARK Study on French Health Insurance Data (2013-2017)
BOTOX® Abstracts
OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study
Neutralizing Antibody Conversion with OnabotulinumtoxinA from Global Studies Across Multiple Indications with a Focus on Movement Disorders: A Meta-Analysis
Benefits of Treatment with OnabotulinumtoxinA in Naive and Non-Naive Patients with Cervical Dystonia are Sustained Over Time: Preliminary Completer Analysis from CD PROBE
Impact of Disease Severity on Presentation Subtype and OnabotulinumtoxinA Utilization in Patients with Cervical Dystonia: Results from the CD PROBE Completer Population
A Cell-Penetrating Peptide (CPP) Did Not Decrease 150-kDa BoNT/A Toxin Adsorption to Surfaces or Increase Toxin Potency or Duration in a Prototype Formulation
OnabotulinumtoxinA Exhibits Greater Efficacy Compared to Purified Botulinum Neurotoxin A (Bont/A-150 KDA) in Peripheral Pain Models
Disease State Abstracts
Classification of Advanced Parkinson’s Disease in OBSERVE-PD Patients Based on the MANAGE-PD Screening Tool
COVID-19 Pandemic Impact on Advanced Parkinson’s Disease in the US
Current Perspectives on the Management of Cervical Dystonia Among Global Clinicians
Tags: < Corporate Events
ShareTweetShareSend

Related Industries

Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023
Healthcare

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023
Healthcare

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023
Healthcare

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023
Healthcare

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023
Healthcare

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

May 10, 2023

3M enters agreements with Pierrel for the sale of assets associated with the dental local anesthetic business

May 3, 2023

...

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023

...

IBM’s The Weather Company Continues to Be the World’s Most Accurate Forecaster Overall, Despite Growing Competition and Amid Weather’s Increased Impact

May 16, 2023

...

Summit Next Gen To Use Honeywell Ethanol To Jet Fuel Technology For Production Of Sustainable Aviation Fuel

May 16, 2023

...

GE Announces Chief Financial Officer Transition; Names Rahul Ghai Chief Financial Officer

May 19, 2023

...

ABB opens Robert M. Thomas Innovation Center in Memphis

May 19, 2023

...

GE Hitachi Announces Intent to Transfer Ownership of Vallecitos Nuclear Center

May 10, 2023

...

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023

...

Benjamin Michajlyszyn Joins Hyundai Motor North America as Director, Safety Test and Investigations Laboratory

May 18, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.